- Home
- GDDY vs EXEL Comparison
GDDY vs EXEL Comparison
Compare GDDY & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDDY | EXEL |
|---|---|---|
| Founded | 1997 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 12.7B |
| IPO Year | 2014 | 2000 |
Fundamental Metrics
Financial Performance| Metric | GDDY | EXEL |
|---|---|---|
| Price | $100.49 | $54.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 21 |
| Target Price | ★ $136.44 | $46.50 |
| AVG Volume (30 Days) | 2.2M | ★ 2.6M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | ★ 3.43 | 1.60 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | $7.94 | $13.61 |
| Revenue Next Year | $6.10 | $13.13 |
| P/E Ratio | ★ $28.30 | $33.80 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $71.59 | $33.76 |
| 52 Week High | $148.51 | $57.57 |
Technical Indicators
Market Signals| Indicator | GDDY | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 59.03 | 53.04 |
| Support Level | $81.16 | $54.30 |
| Resistance Level | $106.00 | $57.12 |
| Average True Range (ATR) | 3.86 | 1.61 |
| MACD | 0.48 | 0.18 |
| Stochastic Oscillator | 90.43 | 64.87 |
Price Performance
Historical ComparisonAbout GDDY GoDaddy Inc.
GoDaddy Inc provides digital solutions and services for entrepreneurs, small businesses, individuals, organizations, developers, designers, and domain investors. It offers tools intended to support business creation and management through an integrated service platform. The company operates through two segments: Applications and Commerce (A&C) and Core Platform (Core). The majority of the company's revenue is derived from the Core Platform segment, which consists of sales of domain registrations and renewals, aftermarket domain sales, website hosting products and website security products. Geographically, it generates the maximum revenue from the United States.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.